Acalabrutinib
- Generic Name
- Acalabrutinib
- Brand Names
- Calquence
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23N7O2
- CAS Number
- 1420477-60-6
- Unique Ingredient Identifier
- I42748ELQW
- Background
To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others.
...
- Indication
Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy. It has also been recently approved for chronic lymphocytic leukemia and small lymphocytic lymphoma.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma
- Associated Therapies
- -
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-12-27
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 39
- Registration Number
- NCT03788291
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Swedish Medical Center
- Target Recruit Count
- 47
- Registration Number
- NCT03736616
- Locations
- 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT03623373
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
- Conditions
- Interventions
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 72
- Registration Number
- NCT03580928
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Stamford Hospital/Bennett Cancer Center, Stamford, Connecticut, United States
🇺🇸Lifespan Cancer Institute, Providence, Rhode Island, United States
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
- Conditions
- Interventions
- First Posted Date
- 2018-05-17
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 30
- Registration Number
- NCT03527147
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Acalabrutinib with or Without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 120
- Registration Number
- NCT03516617
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Study Of The Selective PKC-β Inhibitor MS- 553
- Conditions
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- MingSight Pharmaceuticals, Inc
- Target Recruit Count
- 63
- Registration Number
- NCT03492125
- Locations
- 🇺🇸
University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Columbia University, Herbert Irving Comprehensive Cancer Center, New York, New York, United States
🇺🇸MD Anderson Cancer Center, Department of Leukemia, Houston, Texas, United States
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 11
- Registration Number
- NCT03328273
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 25
- Registration Number
- NCT03205046
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT03198650
- Locations
- 🇯🇵
Research Site, Suita-shi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.